Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTIE E MATTER

Allopathic & Osteopathic Physicians Dermatology

NPI
1598745465
CMS profile
118034
Location
PROSPER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,251.64

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,251.64 113

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTIE E MATTER

NPI 1598745465 · CMS profile ID 118034

Allopathic & Osteopathic Physicians / Dermatology

PROSPER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598745465?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTIE E MATTER, NPI 1598745465, CMS profile ID 118034. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598745465?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CHRISTIE E MATTER, NPI 1598745465, CMS profile ID 118034. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598745465?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CHRISTIE E MATTER, NPI 1598745465, CMS profile ID 118034, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1598745465?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $2,251.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–113 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $15.6002/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671893053 CMS
UCB, Inc. $22.8502/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688252853 CMS
Encore Dermatology Inc. $22.0002/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698861107 CMS
TARO PHARMACEUTICALS USA, INC. $19.2902/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704148915 CMS
EPI Health, LLC $19.5202/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660677417 CMS
Celgene Corporation $11.5401/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672722819 CMS
GENZYME CORPORATION $19.9101/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694276117 CMS
Sun Pharmaceutical Industries Inc. $11.1501/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704599677 CMS
Encore Dermatology Inc. $15.6501/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698861097 CMS
AbbVie, Inc. $15.3301/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647837951 CMS
Novartis Pharmaceuticals Corporation $13.2401/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659803141 CMS
Galderma Laboratories, L.P. $14.0801/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687701239 CMS
AbbVie, Inc. $23.6101/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647837949 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,251.64 113
PY2020 $1,882.49 75
PY2021 $2,093.47 56
PY2022 $1,608.54 58
PY2023 $1,973.69 80
PY2024 $2,451.16 97
PY2025 $3,217.13 133

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $165,944.82 88
PY2024 Principal investigator $14,200.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,979.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525305
Principal investigator 1 Incyte Corporation $2,026.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525309
Principal investigator 1 Incyte Corporation $2,112.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525312
Principal investigator 1 Incyte Corporation $2,112.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525317
Principal investigator 1 Incyte Corporation $1,785.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525392
Principal investigator 1 Incyte Corporation $1,810.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525395
Principal investigator 1 Incyte Corporation $1,810.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525399
Principal investigator 1 Incyte Corporation $3,280.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525496
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525516
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525520
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525524
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525527
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525531
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525535
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525539
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525544
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525548
Principal investigator 1 Incyte Corporation $2,252.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525572
Principal investigator 1 Incyte Corporation $1,896.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525585
Principal investigator 1 Incyte Corporation $1,896.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525589
Principal investigator 1 Incyte Corporation $1,896.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525593
Principal investigator 1 Incyte Corporation $1,896.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525597
Principal investigator 1 Incyte Corporation $1,896.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525601
Principal investigator 1 Incyte Corporation $1,896.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525605
Principal investigator 1 Incyte Corporation $388.00 12/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525407
Principal investigator 1 Incyte Corporation $931.00 12/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525411
Principal investigator 1 Incyte Corporation $1,023.00 12/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525419
Principal investigator 1 Incyte Corporation $3,808.00 12/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525580
Principal investigator 1 SANOFI PASTEUR INC. $800.00 12/02/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112452
Principal investigator 1 SANOFI PASTEUR INC. $1,007.00 12/01/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112876
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525298
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525302
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525321
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525325
Principal investigator 1 Incyte Corporation $169.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525329
Principal investigator 1 Incyte Corporation $169.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525333
Principal investigator 1 Incyte Corporation $169.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525337
Principal investigator 1 Incyte Corporation $169.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525341
Principal investigator 1 Incyte Corporation $2,252.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525345
Principal investigator 1 Incyte Corporation $2,252.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525348
Principal investigator 1 Incyte Corporation $2,252.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525353
Principal investigator 1 Incyte Corporation $1,979.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525373
Principal investigator 1 Incyte Corporation $1,979.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525377
Principal investigator 1 Incyte Corporation $1,979.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525381
Principal investigator 1 Incyte Corporation $1,979.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525385
Principal investigator 1 Incyte Corporation $1,979.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525388
Principal investigator 1 Incyte Corporation $53.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525468
Principal investigator 1 Incyte Corporation $53.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525473
Principal investigator 1 Incyte Corporation $53.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525477
Principal investigator 1 Incyte Corporation $53.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525480
Principal investigator 1 Incyte Corporation $53.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525484
Principal investigator 1 Incyte Corporation $53.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525488
Principal investigator 1 Incyte Corporation $2,112.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525552
Principal investigator 1 Incyte Corporation $2,112.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525555
Principal investigator 1 Incyte Corporation $2,112.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525559
Principal investigator 1 Incyte Corporation $2,112.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525563
Principal investigator 1 SANOFI PASTEUR INC. $2,619.72 11/21/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112865
Principal investigator 1 SANOFI PASTEUR INC. $30,788.65 11/14/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112841
Principal investigator 1 Incyte Corporation $1,500.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525403
Principal investigator 1 Incyte Corporation $5,000.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525423
Principal investigator 1 Incyte Corporation $10,000.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525444
Principal investigator 1 Incyte Corporation $2,500.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525567
Principal investigator 1 Incyte Corporation $2,000.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525576
Principal investigator 1 SANOFI PASTEUR INC. $1,152.45 11/05/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112782
Principal investigator 1 SANOFI PASTEUR INC. $300.00 10/29/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112488
Principal investigator 1 Incyte Corporation $2,252.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525357
Principal investigator 1 Incyte Corporation $2,252.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525361
Principal investigator 1 Incyte Corporation $2,252.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525364
Principal investigator 1 Incyte Corporation $2,252.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525369
Principal investigator 1 Incyte Corporation $133.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525416
Principal investigator 1 Incyte Corporation $86.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525426
Principal investigator 1 Incyte Corporation $53.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525431
Principal investigator 1 Incyte Corporation $53.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525435
Principal investigator 1 Incyte Corporation $53.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525439
Principal investigator 1 Incyte Corporation $3,280.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525448
Principal investigator 1 Incyte Corporation $3,280.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525453
Principal investigator 1 Incyte Corporation $3,280.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525457
Principal investigator 1 Incyte Corporation $3,280.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525461
Principal investigator 1 Incyte Corporation $3,280.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525465
Principal investigator 1 Incyte Corporation $194.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525491
Principal investigator 1 Incyte Corporation $169.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525500
Principal investigator 1 Incyte Corporation $169.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525503
Principal investigator 1 Incyte Corporation $169.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525507
Principal investigator 1 Incyte Corporation $169.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT ZOMNIR FAMILY MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525511
Principal investigator 1 SANOFI PASTEUR INC. $3,218.14 04/23/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112600
Principal investigator 1 SANOFI PASTEUR INC. $500.00 04/23/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112607
Principal investigator 1 SANOFI PASTEUR INC. $1,220.86 03/20/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112575
Principal investigator 1 SANOFI PASTEUR INC. $300.00 01/09/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112589